Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 8.2% in January

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 3,840,000 shares, a growth of 8.2% from the December 31st total of 3,550,000 shares. Based on an average trading volume of 463,300 shares, the short-interest ratio is presently 8.3 days.

Aldeyra Therapeutics Trading Down 3.0 %

Shares of Aldeyra Therapeutics stock traded down $0.16 on Friday, reaching $5.24. 325,410 shares of the company’s stock were exchanged, compared to its average volume of 310,576. The firm’s 50-day moving average is $5.01 and its two-hundred day moving average is $5.08. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics has a 52 week low of $2.71 and a 52 week high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). Analysts forecast that Aldeyra Therapeutics will post -0.92 earnings per share for the current year.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of hedge funds have recently modified their holdings of the business. Jacobs Levy Equity Management Inc. grew its holdings in Aldeyra Therapeutics by 163.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after purchasing an additional 295,864 shares during the last quarter. International Assets Investment Management LLC grew its position in Aldeyra Therapeutics by 397.0% in the third quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock worth $15,480,000 after acquiring an additional 229,487 shares during the period. Barclays PLC grew its holdings in shares of Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 48,313 shares in the last quarter. AlphaCentric Advisors LLC acquired a new stake in shares of Aldeyra Therapeutics in the 4th quarter valued at $234,000. Finally, American Century Companies Inc. boosted its stake in Aldeyra Therapeutics by 216.7% in the second quarter. American Century Companies Inc. now owns 53,388 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 36,528 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.